A Pilot Study on the Prevention of the Vascular RISK Related to Atrial Fibrillation After Intracranial Hemorrhage by Closing the Left Auricle
RIVAFAG
1 other identifier
interventional
58
1 country
1
Brief Summary
Atrial fibrillation (AF) is a frequent heart rhythm disorder, responsible for the formation of cardiac thrombi, which can embolize in the systemic circulation, responsible for strokes (Cerebrovascular accidents). AF increases the risk of stroke and stroke-related disability. Preventing the thromboembolic risk associated with FMD is therefore a public health issue. The reference treatment is oral anticoagulation but this treatment is contraindicated in patients with a history of intracranial hemorrhage. The percutaneous closure of the auricle is a recent technique which makes it possible to exclude this appendix from the left atrium where the majority of thrombi are formed in the framework of the AF. Comparative studies have shown the effectiveness of this technique, appearing to be similar to that of anticoagulation. However, in view of the per-procedural risk, the indication of closure was retained by the health authorities only in the event of a contraindication to oral anticoagulants in patients with non-valvular AF with a high thromboembolic risk. Patients with a history of intracranial hemorrhage are therefore candidates for this technique, but there are few studies where these patients were included. The risk-benefit must be demonstrated over the long term, in terms of ischemic, hemorrhagic recurrence and becoming functional and cognitive.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable atrial-fibrillation
Started Jul 2016
Shorter than P25 for not_applicable atrial-fibrillation
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 14, 2016
CompletedFirst Submitted
Initial submission to the registry
April 7, 2017
CompletedFirst Posted
Study publicly available on registry
April 13, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 19, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 19, 2017
CompletedNovember 19, 2025
November 1, 2025
1.3 years
April 7, 2017
November 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Compare the risk of vascular event (ischemic stroke, haemorrhagic stroke, systemic embolism or cardiovascular or indeterminate death) in patients treated at the Amiens University Hospital with a history of AF and intracranial haemorrhage
1 hours
Study Arms (2)
Patients with pericardial closure of the auricle
OTHERPatients without closure of the auricle
OTHERInterventions
Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales. Analysis of selected therapeutic options for the prevention of AF ischemic events.
Eligibility Criteria
You may qualify if:
- Patients aged 18 years or older
- Affiliation to a social security scheme
- Non-valvular, paroxysmal, persistent or permanent atrial fibrillation
- CHA2DS2-VASc greater than or equal to 2
- History of intracranial haemorrhage: Intra-parenchymal hematoma, subacute or chronic subcutaneous hematoma And
- Patients having benefited from the percutaneous closure of the auricle at the University Hospital of Amiens
- Either patient admitted to the CHU of Amiens in neurology, neurosurgery or geriatrics for intracranial haemorrhage, who received standard medical treatment for the comparison group.
You may not qualify if:
- CHADS2VASC2 less than 2
- Extradural hematoma
- Arachnoidal haemorrhage by rupture of aneurysm
- Haemorrhagic transformation of ischemic stroke
- Other indication of anticoagulation than FA
- Modified Rankin scale greater than 4 following intracranial hemorrhage.
- Early death, in the month following the onset of intracranial hemorrhage.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens Picardie
Amiens, Picardie, 80054, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 7, 2017
First Posted
April 13, 2017
Study Start
July 14, 2016
Primary Completion
October 19, 2017
Study Completion
October 19, 2017
Last Updated
November 19, 2025
Record last verified: 2025-11